Effectiveness of Shengmai Injection on angina pectoris based on real-world propensity score method

Objective:Shengmai injection is a commonly used traditional Chinese medicine for the treatment of angina pectoris.However,there is still a lack of high-quality clinical research evidence for the treatment effect of Shengmai injection for angina pectoris.Real-world studies based on large samples can provide Shengmai injection.Researches on the treatment of angina pectoris with Shengmai injection provide important evidence.Methods:This article is based on the information collected by the hospital information system(HIS)database of 22 tertiary A general hospitals for all patients who used Shengmai injection and those who did not use Shengmai injection.The propensity scoring method was used to evaluate the possible existence of the research data.The confounding factors are controlled.Through the general Logistic regression analysis method,the propensity score weighted Logistic regression analysis method and the propensity score weighted Logistic regression analysis method with covariates,the therapeutic effect of Shengmai injection on angina pectoris was explored.Results:Three kinds of logistic regression analysis showed that there were statistical differences in the treatment effect of Shengmai injection on angina pectoris in the group without Shengmai injection.Propensity score weighted logistic regression analysis with covariates balanced the effect of multiple confounding factors.Using real-world data to construct a retrospective cohort study confirmed the clinical effectiveness of Shengmai injection in the treatment of angina pectoris,and at the same time confirmed the wide application of Shengmai injection in angina pectoris complicated with multiple organ failure.Conclusion:Shengmai injection is effective in the treatment of angina pectoris.The weighted method of propensity score removes confounding factors,which improves the reliability of real-world research results.

Association rules analysis of Fufang Kushen injection in combination with traditional Chinese medicine or modern medications in treating Cervical cancer: real-world retrospective study

Objective: The present study aimed to analyze the association rules of Fufang Kushen injection in combination with other traditional Chinese medicine ( TCM) or modern medications in treating cervical cancer (CC) based on the electrical medical records extracted from real-world hospital information system. Methods: The clinicians’ prescriptions regarding to the combination of with TCM or modern medications were from hospital information system electronic medical data integration warehouse established by the Institute of Basic Medical Research of Chinese Medicine, China Academy of Chinese Medical Sciences, which integrated the hospital information system data of 22 hospitals. The association rules of the drug characteristics were analyzed through Apriori algorithm. Results: A total of 839 patients with CC were included. We found that is often combined with prescriptions which could clear heat, remove toxicity, supplement Qi. also combined with chemotherapeutic drugs, immunomodulatory drugs, 5-HT receptor blockers, and glucocorticoids. The combination presents a specific law. Conclusion: Fufang Kushen injection combined with hepatoprotective drugs, immunomodulators and glucocorticoids is often used to treat cervical cancer.

Clinical Evaluation on Xiyanping Injection in the Treatment of Bronchopneumonia in Children Based on Meta-Analysis

Objective:The aim of this study is to evaluate the effectiveness and safety of xiyanping injection(XYPI)in the treatment of children with bronchopneumonia.Methods:Asystematic and comprehensive search was conducted in the domestic and foreign electronic databases CNKI,SinoMed,VIP,WanFang DATA,PubMed,The Cochrane Library,Embase,Web of Science,Clinical‑Trials.gov,and the search date ended on May 30,2019.Inclusion criteria:(1)the types of studies included were randomized controlled trials;(2)the study participants were infants and children with a clear diagnosis of bronchopneumonia,without gender and ethnic restrictions;(3)the intervention test group was XYPI or the control group plus XYPI.The control group was routine treatment(RT)(basic treatment such as fever,cough and asthma,oxygen inhalation,anti‑infection,maintaining water,electrolyte balance,etc.)or other Western medicine or RT+other Western medicine treatment.Except for XYPI,the two groups were consistent in intervention measures.According to the Cochrane Handbook,5.1 evaluation standard and a meta‑analysis of the final included studies was performed using RevMan 5.3 software.Results:Atotal of 57 studies were included,with a total sample size of 8454 cases,of which 4255 were in the experimental group and 4199 were in the control group.Meta‑analysis results showed that(1)Total effective rate:XYPI group was better than the control group(relative risk[RRRT]=1.25,95%confidence interval[CI][1.15,1.36],P<0.00001;RRRT+RBVI=1.18,95%CI[1.09,1.29],P<0.0001;RR antibiotic=1.16,95%CI[1.09,1.24],P<0.00001,RRRT+antibiotic=1.22,95%CI[1.16,1.27],P<0.00001);antipyretic time:XYPI group was better than the control group(mean difference[MDRT]=−0.97,95%CI[−1.17,−0.76],P<0.00001;MDRT+antibiotic=−2.28,95%CI[−2.88,−1.67],P<0.00001;MDRT+RBVI=−1.51,95%CI[−1.81,−1.21],P<0.00001;cough disappearing time:XYPI group was better than the control group(MDRT=−1.37,95%CI[−1.74,−1.00],P<0.00001;MDRT+antibiotic=−1.71,95%CI[−2.04,−1.37],P<0.00001;MDRT+RBVI=−1.51,95%CI[−2.15,−0.86],P<0.00001);disappearance time of lung rales:XYPI group was better than the control group(MDRT=−1.11,95%CI[−1.35,−0.88],P<0.00001;MDRT+RBVI=−1.63,95%CI[−2.23,−1.03],P<0.00001).The difference was statistically significant;(2)Of the 57 studies(a total of 8454 cases),29 studies reported adverse reactions,of which 18 studies did not find adverse reactions,and 11 studies reported adverse reactions such as nausea,vomiting,and rash after medication in both groups.(3)The funnel chart indicated potential publication bias.Conclusion:Based on the existing clinical evidence,XYPI can have a certain effect on the treatment of children with bronchopneumonia,and it is not yet possible to conclude its safety evaluation.Moreover,due to the low quality of the included studies,this evidence is still used with cautious clinically.

Systematic Review and Meta-analysis of Shenfu Injection on Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease

The objective of the study was to systematically evaluate the efficacy and safety of Shenfu injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).A total of 15 randomized controlled trials involving 1198 patients were included.The results of meta-analysis showed that compared with the control group,the experimental group can improve the total clinical effective rate in AECOPD patients(relative risk=1.15,95%confidence interval[CI][1.09,1.21],P<0.00001),improve the pulmonary function levels:forced expiratory volume in one second(FEV1)(standardized mean difference=1.88,95%CI[0.89,2.88],P=0.0002)and the FEV1/forced vital capacity(FVC)ratio(FEV1/FVC)(mean difference[MD]=3.96,95%CI[2.74,5.19],P<0.00001);improve the arterial blood oxygen partial pressure(MD=6.03,95%CI[4.58,7.48],P<0.00001),and reduce the arterial blood partial pressure of carbon dioxide(MD=-4.59,95%CI[-6.91,-2.26],P=0.00001),and the white blood cell count in pulmonary infection may be improved(MD=-1.16,95%CI[-1.63,-0.68],P<0.00001).The study showed that the efficacy of experimental group in the treatment of AECOPD is better than control group.Due to the limitation of the number and quality of included studies,this conclusion needs more high quality studies to confirm.

Risk Factors Associated with Recurrence within 90 Days of Ischemic Stroke Onset in Chinese Medicine Hospital: A National Cross-Sectional Study in China

Objective:The short-and long-term risk factors for stroke recurrence may be different.This study is aimed to determine the risk factors for recurrence within 90 days in patients with ischemic stroke in China.Method:This was cross-sectional registry-based study in Chinese medicine hospitals from eight provinces and ten cities in China between November 3,2016 and May 28,2018.Two thousand one hundred and twenty patients with ischemic stroke aged between 35 and 80 years.Stroke recurrence was defined as an outcome indicator.Computed tomography/magnetic resonance imaging was used as a diagnostic tool for stroke recurrence.Patients’age,sex,height,weight,body mass index(BMI),education level,medical history,family history,smoking,and drinking were recorded.Routine laboratory examinations were performed.Associated factors were investigated by calculating the odds ratio(OR)using logistic regression modeling.Results:In all,2120 patients were included in the study,712(33.6%)of whom were women and 1408(66.4%)were men,with a mean age of 62.84±9.35 years.Eighty-two patients experienced stroke recurrence within 90 days,and the accumulative recurrence rates of stroke were 3.9%(95%confidence interval[CI],3.0%–4.7%).The binary logistic analysis showed that previous history of one(OR=8.113;95%CI,4.497–14.637),two(OR=8.848;95%CI,4.025–9.449),or≥3 ischemic strokes(OR=24.599;95%CI,9.307–65.018),and BMI<18.5 kg/m2(OR=2.842;95%CI,1.000–8.075)were independently associated with stroke recurrence within 90 days.Conclusions:The accumulative recurrence rate of ischemic stroke was 3.9%within 90 days.Number of previous history of ischemic stroke and BMI<18.5 kg/m2 were independent risk factors for stroke recurrence.Medical history and solar terms of ischemic stroke were not found to be associated with stroke recurrence within 90 days.Effective secondary prevention for patients with a previous history of ischemic stroke is urgently needed to address this stroke recurrence burden.